Suggested remit: To appraise the clinical and cost effectiveness of cemiplimab with chemotherapy within its marketing authorisation for untreated advanced or metastatic NSCLC.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3949

Provisional Schedule

Committee meeting 12 February 2025
Expected publication 30 April 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Newcastle NIHR TAR Team, Newcastle University

Stakeholders

Companies sponsors Regeneron (cemiplimab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group (BTOG)
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Bristol Myers Squibb (paclitaxel) – confidentiality agreement not signed, not participating
  Eli Lilly (pemetrexed) – confidentiality agreement not signed, not participating
  Hospira UK (carboplatin, paclitaxel) – confidentiality agreement not signed, not participating
  Medac (vinorelbine) – confidentiality agreement not signed, not participating
  MSD (pembrolizumab)
  Pierre Fabre (vinorelbine) – confidentiality agreement not signed, not participating
  Pfizer (pemetrexed, cisplatin, carboplatin, gemcitabine) – confidentiality agreement not signed, not participating
  Ranbaxy (gemcitabine, pemetrexed) – confidentiality agreement not signed, not participating
  Roche (atezolizumab, bevacizumab) – confidentiality agreement signed, participating
  Seacross Pharmaceuticals (paclitaxel) – confidentiality agreement not signed, not participating
  Sandoz (cisplatin) – confidentiality agreement not signed, not participating
  Synchrony Pharma (gemcitabine) – confidentiality agreement not signed, not participating
  Teva UK (paclitaxel) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
10 July 2024 Invitation to participate
25 April 2024 Please note that following on from conversation between NICE and the company, the timelines for this appraisal have been scheduled and the appraisal is now anticipated to begin in early July 2024 when we will write to you about how you can get involved.
13 February 2024 - 12 March 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3949
13 February 2024 In progress. Scoping commencing
18 August 2022 Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949]. For information the company have advised that they will not be making a submission. Therefore, in collaboration with the company, NICE has suspended this evaluation from its current work programme. As this evaluation has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual